115450.KQ
HLB Therapeutics Co.,Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 2,095.00
+0.96%Year over year
Reported trailing growth
- Revenue
- +5.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +38.7%
- Operating cash flow
- +22.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +18.0%
- EBITDA
- -60.4%
- EBIT
- +53.0%
- Net income
- +59.5%
- EPS
- +63.7%
- Free cash flow
- +6.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026